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Abstract
Although prostate cancer (PCa) is the second leading cause of cancer death among men worldwide, not all men
diagnosed with PCa will die from the disease. A critical challenge, therefore, is to distinguish indolent PCa frommore
advanced forms to guide appropriate treatment decisions. We used Enhanced Reduced Representation Bisulfite
Sequencing, a genome-wide high-coverage single-base resolution DNAmethylation method to profile seven localized
PCa samples, seven matched benign prostate tissues, and six aggressive castration-resistant prostate cancer (CRPC)
samples. We integrated these data with RNA-seq and whole-genome DNA-seq data to comprehensively charac-
terize the PCa methylome, detect changes associated with disease progression, and identify novel candidate prog-
nostic biomarkers. Our analyses revealed the correlation of cytosine guanine dinucleotide island (CGI)–specific
hypermethylation with disease severity and association of certain breakpoints (deletion, tandem duplications, and
interchromosomal translocations) with DNA methylation. Furthermore, integrative analysis of methylation and
single-nucleotide polymorphisms (SNPs) uncovered widespread allele-specific methylation (ASM) for the first time
in PCa. We found that most DNA methylation changes occurred in the context of ASM, suggesting that variations
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in tumor epigenetic landscape of individuals are partly mediated by genetic differences, whichmay affect PCa disease
progression. We further selected a panel of 13 CGIs demonstrating increased DNAmethylation with disease progres-
sion and validated this panel in an independent cohort of 20 benign prostate tissues, 16 PCa, and 8 aggressive CRPCs.
These results warrant clinical evaluation in larger cohorts to help distinguish indolent PCa from advanced disease.
Neoplasia (2013) 15, 373–383
Introduction
Prostate cancer (PCa) is the most common cancer in men worldwide
[1]. Although 1 in 6 men will likely be diagnosed with PCa during
his lifetime, only 1 in 36 will ultimately die from the disease, reflect-
ing a 5-year survival rate close to 100% [2]. Overtreatment is a major
concern in PCa, as many patients diagnosed with clinically localized
PCa do not require definitive treatment [3,4]. Patients presenting
with advanced forms, including metastatic and castration-resistant
prostate cancer (CRPC), however, have much worse outcomes; there-
fore, distinguishing indolent from advanced PCa has been an impera-
tive task in PCa research.
In this study, we sought to investigate how genome-wide DNA
methylation patterns might help differentiate between indolent and
advanced PCa. We also reasoned that single-nucleotide resolution
analysis of DNA methylation might provide mechanistic insights into
the evolution of PCa toward more advanced forms. DNA methylation
primarily arises at cytosine guanine dinucleotide (CpG) sites and is
associated with epigenetic regulation of gene expression [5]. Perturbed
DNA methylation patterns have been shown to arise during PCa
tumorigenesis and have been implicated in PCa etiology and disease
progression [6]. DNA methylation profiling studies using microarrays,
MethylPlex–next-generation sequencing, and MeDIP-Seq have indeed
identified a large number of DNA methylation changes in PCa [7–11].
However, few studies have investigated DNA methylation changes
in CRPC, in part due to limited availability of tissues. DNA hypo-
methylation has been found to occur during PCa progression by
evaluating 5-methylcytosine content in genomic DNA, while hyper-
methylation at certain CpG island (CGI) promoter genes were found
in both localized PCa and metastatic PCa [10,12–14]. An array-based
DNA methylation profiling study of CRPC recently found that altera-
tions in DNA methylation arose more frequently than mutations or
copy number changes [15], further strengthening the rationale for
interrogating metastatic PCa to identify biomarkers of DNA methyla-
tion related to PCa disease progression. To our knowledge, the present
study is the first to perform broad coverage single-nucleotide resolution
analysis of CRPC.
We previously used next-generation sequencing to characterize the
whole genome and transcriptome of seven clinically localized PCa
together with matched benign adjacent prostate tissues as well as of
seven CRPC cases [16,17]. In an effort to understand how aberrant
DNAmethylation may contribute to PCa and to the metastatic pheno-
type, we profiled the global DNA methylation patterns of these same
cases using Enhanced Reduced Representation Bisulfite Sequenc-
ing (ERRBS). ERRBS with single-base resolution gives a broader
genome-wide coverage by extending to CGI shores, compared to
Reduced Representation Bisulfite Sequencing [18]. Since bisulfite
sequencing provides single-base resolution, it allowed us to investigate
how frequently allele-specific methylation (ASM) occurs in genetically
and epigenetically unstable PCa and CRPC samples. ASM is mainly
studied in the context of genomic imprinting, whose role is to ensure
and maintain parent-of-origin effects on gene expression in a small set
of genes [19,20]; its occurrence in non-imprinted genomic regions of
cancer cells is less clear. In this study, we integrated data of methylation
and SNPs to delineate and understand ASM in clinical PCa cases.
We report novel insights into DNA methylation patterns in PCa
progression, association between DNA methylation and breakpoints,
ASM changes, and the identification of a panel of CGIs highly related
to PCa progression. We propose that differential methylation changes
could be used not only as early detection biomarkers but also as new
prognostic biomarkers in assisting treatment management decisions.
Materials and Methods
Prostate Tissue Samples
All tissue samples (benign prostate tissues and PCa and CRPC sam-
ples) were collected as part of an Institutional Review Board–approved
protocol at Weill Cornell Medical College (WCMC). PCa (hormone
naïve PCa) and CRPC were obtained, and DNA extraction was per-
formed as previously described [16,17]. None of the PCa samples were
from patients who received preoperative hormonal therapy, chemo-
therapy, or radiotherapy. Hematoxylin and eosin (H&E) slides of
each prostate tissue sample were evaluated by the study’s pathologists
(M.A.R., K.P., and J.M.M.) to determine areas of benign and cancer;
tumors were selected for high-density cancer foci (>90% tumor tissue).
Biopsy cores (1.5 mm) from frozen tissue blocks (ERRBS) or formalin-
fixed, paraffin-embedded (FFPE) blocks (validation) were prepared for
DNA extraction. Table W1 shows Gleason grade, age, preoperative
serum prostate-specific antigen levels, and staging of all of the patients
from whom prostate tissues were obtained for this study. Seven sepa-
rately collected benign prostatic tissue samples matched to the cancer
tissues (obtained from the same patients) were used as normal con-
trols. Samples for the validation cohort consisted of 20 benign prostate
tissues and 16 PCa and 8 CPRC samples. The benign prostate tissues
also came from the matched PCa and CRPC patients. All CRPC
samples were from patients with variable degrees of neuroendocrine
differentiation, and three of the eight cases were pure neuroendocrine
histology and lacked protein androgen receptor (AR) expression. The
PCa samples used in ERRBS were from patients without any recur-
rence following radical prostatectomy for 5 to 6 years and 3 to 7 years
for the PCa patients in the validation cohort (surgeries performed be-
tween 2006 and 2010). Benign prostate tissues were benign glands
from a cancer-free region of the matched PCa or CRPC patients, taken
from a separate frozen or FFPE tissue block without a cancer region as
determined by the study’s pathologists. DNA from FFPE blocks was
extracted using theDNeasy Blood andTissue Kit (Qiagen, Germantown,
MD) according to the manufacturer’s instructions and then evaluated
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by the FFPE Quality Control Kit (Illumina, San Diego, CA). Samples
that passed the quality control (QC) test were used in the validation.
Clinical parameters of samples used in ERRBS and the validation study
are listed in Tables W1 and W2.
Enhanced Reduced Representation Bisulfite Sequencing
Sample preparations were performed at the WCMC Epigenomics
Core Facility as previously described [18]. In brief, the preparation steps
included: 1) MspI enzyme digestion; 2) end repair of digested DNA;
3) adenylation; 4) adapter ligation, with pre-annealed 5-methylcytosine–
containing Illumina adapters; 5) isolation of library fragments of 150
to 400 bp from a 1.5% agarose gel (using low-range ultra-agarose from
Bio-Rad, Des Plaines, IL); 6) bisulfite conversion using the EZ DNA
Methylation Kit (Zymo Research, Irvine, CA) with the following
changes: i) CT conversion incubation in a thermocycler (Eppendorf,
Hauppauge, NY) with the condition: 30 seconds at 95°C followed by
15 minutes at 50°C for 55 cycles, and ii) elution into nuclease-free
water; 7) polymerase chain reaction (PCR) amplification; each library
was prepared with FastStart High Fidelity DNA Polymerase (Roche,
Indianapolis, IN) and Illumina PCRprimers PE1.0 and 2.0. The thermo-
cycler conditions were given as follows: 5 minutes at 94°C, 18 cycles
of 20 seconds at 94°C, 30 seconds at 65°C, 1 minute at 72°C, followed
by 3 minutes at 72°C. PCR products were isolated using Agencourt
AMPure XP (Beckman Coulter, Brea, CA) beads per manufacturer’s
recommended protocol (Agencourt) All amplified libraries were eval-
uated using a Qubit 1.0 fluorometer and Quant-iT dsDNA HS Assay
Kit (Invitrogen, Grand Island, NY) for quantitation and bioanalyzer
visualization (Agilent 2100 Bioanalyzer; Agilent, Santa Clara, CA).
TheWCMCComputationalGenomicsCore Facility supported ERRBS
data analysis.
Quantitative DNA Methylation Analysis by
MassARRAY EpiTYPER
Measurement of DNA methylation levels was performed at the
WCMC Epigenomics Core Facility with matrix-assisted laser desorp-
tion ionization/time-of-flight mass spectrometry using MassARRAY
EpiTYPER assays (Sequenom, San Diego, CA) as previously described
[21]. Genomic DNA was bisulfite-converted using the EZ DNA
Methylation Kit according to the manufacturer’s protocol (Zymo
Research). The spectra’s methylation ratios were then calculated using
EpiTYPER software v1.0 (Sequenom). The EpiTYPER primers were
designed through the Sequenom EpiDesigner web site at http://www.
epidesigner.com/start3.html. The reverse primers were taggedwith a T7
promoter sequence: cagtaatacgactcactatagggagaaggct. EpiTYPER primer
sequences are listed in Table W4.
Computational Approaches
Bisulfite-treated read alignment and methylation calls were per-
formed as previously described [18]. Briefly, bisulfite reads were aligned
to the bisulfite-converted hg19 reference genome using Bismark [22].
All samples had bisulfite conversion rates >99.5%. Differentially methyl-
ated CpGs were identified using the Fisher exact test with correction
for Benjamini-Hochberg multiple testing. Differentially methylated
regions (DMRs) were defined as regions containing at least five dif-
ferentially methylated CpGs [false discovery rate (FDR) = 10%] and
whose total methylation difference was more than 10%. DMRs were
annotated using ChIPseeqerAnnotate from the ChIPseeqer package
[23]. Motif and pathway analyses were performed with default param-
eters using FIRE [24] and iPAGE [25], respectively. When comparing
methylation at CGIs between groups of samples, we used the LIMMA
approach on log-transformed methylation values. Methylation of a spe-
cific region was calculated by averaging the methylation levels of all cov-
ered CpGs in that region. Clonality rates were calculated by counting
how many times rare non-converted cytosine among reads mapped at
the same genomic location and orientation, as described in Gertz et al.
[26]. Random Forests [27] and 10-fold cross-validation were used to
build classification models based on the samples in the validation cohort.
Both classification and the estimation of sensitivity, specificity, and area
under the receiver operating characteristic (ROC) curve [area under curve
(AUC)] were performed in R using the Caret package (at http://caret.
r-forge.r-project.org/).
Data Deposition Statement
The ERRBS data have been deposited for public access in theNational
Center for Biotechnology Information’s (NCBI) gene expression omnibus
(GEO) database and is accessible through GEO Series accession num-
ber GSE41701. DNA-seq and RNA-seq data are available as described
in Beltran et al. and Berger et al. [16,17].
Results
Profound and Widespread Changes in DNA Methylation in
Prostate Adenocarcinoma
We first interrogated seven pairs of localized PCa and their matched
benign prostate tissues. ERRBS provided more than 10-fold sequenc-
ing coverage on >2.5 million CpG sites genome-wide for each sample.
By combining methylation levels from all interrogated CpG sites, we
observed an overall increase in DNA methylation in PCa (Figure 1A),
driven in large part by a sharp and systematic methylation increase
at CGIs (P = .0002). The changes at non-CGI regions (defined as at
least 10 kb away from known CGIs) were more diverse and less sys-
tematic among PCa patients (P = .85); there was a trend toward global
hypomethylation in four of the seven cases. This analysis also indicated
that global methylation levels were significantly more heterogeneous
in PCa compared to benign prostate tissues. We confirmed this hetero-
geneity when we determined DMRs within each pair and detected
differing numbers of hypermethylated and hypomethylated regions
in each case (Figure 1B), with some cases showing more hypomethyl-
ated DMRs while others showed more hypermethylated DMRs. De-
spite this heterogeneity and the different genetic background of each
patient, we found that many hypermethylated and hypomethylated
DMRs resided at the same locations between individuals, suggesting
that aberrant DNA methylation in PCa follows a predetermined path
(Figure 1C ). When we examined DNA methylation patterns across
different genomic regions, we found that hypermethylated DMRs
were mostly enriched at promoters [defined as ±2 kb windows centered
on RefSeq transcription start sites (TSS); Figure 1D]. However, hypo-
methylatedDMRsweremostly located at introns and intergenic regions
(Figure 1E).
We then sought to integrate RNA-seq data performed on the same
samples to examine the relationship between aberrant methylation and
gene expression changes between PCa and matched benign tissue from
the same patient. We found that overall genes located near hyper-
methylated DMRs had decreased expression (P < 1e−31), while genes
near hypomethylated DMRs had increased expression (Figure 1F ; data
shown for patient 1). This indicates that, within controlled isogenic
conditions, the frequently assumed but broadly elusive negative corre-
lation between DNA methylation and gene expression tends to hold.
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We also found that hypermethylated DMRs overlapped strongly
with regions enriched for H3K27me3 in human embryonic stem cells
[28] (Figure 1G ), confirming previous reports of such concurrent
epigenomic changes in PCa cell lines and other cancer types [29–32].
De novo DNA motif analysis was carried out to examine the
sequences of DMRs. We focused the analysis on differentially methyl-
ated CGIs, since these regions behaved in a consistent way across cases
(Figure 1A). We used non-differentially methylated CGIs as con-
trol, thus controlling for CpG content. This analysis identified three
DNA motifs preferentially enriched with hypermethylated DMRs,
including one that resembled the motif bound by the transcription
factor early growth response gene 1 (EGR1; Figure W1A). When
examining RNA-seq data, we found that EGR1 expression levels were
lower in PCa compared to benign prostate tissues (Figure W1B). This
down-regulation was confirmed by immunohistochemistry staining
(Figure W1C). Although more extensive work is required to investigate
the role of EGR1 in PCa, we speculate that EGR1 binding to CGIs
may prevent DNA methylation, while loss of EGR1 expression may
lead to increased DNA methylation.
Structural Variations in PCa Are Correlated with
DNA Methylation Patterns in Benign Tissues
The previously described genomic characterization of our seven PCa
samples provided a unique opportunity to integrate genomic and
epigenomic information and better understand the events that lead
to progression from benign lesion to PCa [17]. To evaluate whether
DNA methylation patterns in normal tissues may influence the for-
mation of genomic alterations that lead to PCa, we examined structural
variation breakpoints that have occurred in PCa and determined their
DNA methylation levels in matched benign prostate tissues. For this
analysis, we examined DNA methylation in 10-kb windows centered
on each breakpoint. We found that in benign tissues, deletion and
tandem duplication breakpoints that occurred in PCa were less methyl-
ated than control random regions (P = .004 and P = .026, respectively);
however, interchromosomal translocation breakpoints were more
methylated than expected (P = .008; Figure 2A). Thus, certain struc-
tural variation breakpoints have non-random methylation levels in
benign prostate tissues, hinting at a potential role of the epigenome
in mediating these alterations. Moreover, Berger et al. found that
CpG sites had significantly higher mutation rate (more than 10-fold)
than all other genomic positions did [17]. When we examined CpGs
that were mutated in PCa samples, we found that these CpGs were
highly methylated in their matched benign tissues (Figure 2B). By
comparison, a random selection of non-mutated CpGs showed much
lower DNA methylation in the benign tissues. Most mutations
occurring at CpGs were C-to-T transition mutations; however, we also
found the less frequent C-to-A and C-to-G transversion mutations.
The C-to-T transition may come from spontaneous deamination of
methylated cytosine to thymidine. While many of these mutations
may be passenger mutations that have been deaminated in the initial
malignant clone, our results altogether suggest that many genetic altera-
tions in PCa have a non-randommethylation signature in normal pros-
tate cells. Moreover, our results suggest that non–C-to-T mutations
at methylated cytosines occur at a non-negligible rate and that highly
methylated CpG sites are inherently fragile and mutation prone, while
non-methylated CpGs are protected from alterations.
Widespread Allele-Specific DNA Methylation in PCa
Taking advantage of single CpG resolution and high coverage pro-
vided by ERRBS, we sought to investigate whether certain regions of
the methylome showed ASM and whether ASM levels differ between
matched tumors and benign tissues. We therefore mined the ERRBS
data and looked for statistical associations between SNPs (defined here
as mismatches between the samples and the reference genome) and
CpG methylation within the same ERRBS reads (Figure 3A). Com-
paring CpGs covered in both benign tissues and matched tumors, we
identified between 60,000 and 150,000 CpGs that coincided with
a heterozygous SNP within the same read and for which we could
perform a statistical test of association (Fisher exact test) [17]. After
correction for multiple testing (Benjamini-Hochberg, FDR = 20%),
we identified several thousand CpGs with ASM in both benign tissues
and PCa. When we compared the fraction of CpGs with ASM, we
observed a significant increase in PCa compared to benign tissues
(P = .0009, t test; Figure 3B). Importantly, we found that unequal
read clonality (PCR duplicates) could not explain these differences, as
clonality levels were approximately equal between PCa and matched
benign tissues (Figure W2).
We speculated that allele-specific changes in methylation could be
responsible for a significant fraction of all changes in DNA methyla-
tion (that is, one allele undergoes methylation changes, while the
other does not). Accordingly, we found that ASM preferentially
occurred in differentially methylated CpGs and DMRs, for both
hypermethylated and hypomethylated (Figure 3, C andD). Altogether,
these results suggest that a large fraction of DNA methylation changes
occur on a single-allele basis. We also sought to determine whether
ASM occurred in the context of allele-specific expression. While we
found overlaps (i.e., genes whose promoter showed ASM and with
different allelic usage between DNA-seq and RNA-seq; not shown),
the coverage differences between ERRBS, DNA-seq, and RNA-seq
data limited the analysis and precluded a definitive conclusion.
DNA Methylation at CGIs Increases with Disease Severity
To examine how DNA methylation patterns may have evolved in
more advanced PCa, we profiled the DNA methylome of six CRPC
samples from patients who failed endocrine therapy and/or developed
a predominantly androgen-independent PCa associated with lack
of AR expression and extensive neuroendocrine differentiation [16].
Examining DNA methylation levels at CGIs, we found that CRPC
Figure 1. Overall increased DNA methylation in PCa, consistent across cases. (A) Percentages of DNA methylation in all regions, CGIs,
and non-CGIs of matched benign prostate tissues (Ben) and PCa. (B) Numbers of hypermethylated or hypomethylated DMRs of indi-
vidual PCa samples. (C) Example of hypermethylated and hypomethylated DMRs, many of which occur independently in different
patients. (D) Percentage of hypermethylated regions occurring within indicated genomic locations. (E) Percentage of hypomethylated
regions occurring within indicated genomic locations. (F) Expression fold changes of nearby genes in regard of hypermethylated or
hypomethylated DMRs (data shown for case 1). (G) Percentage of hypermethylated or hypomethylated DMRs overlapped with
H3K27me3 peaks in human embryonic stem cells (hESC).
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had higher levels compared to PCa (Figure 4A). Taken together, our
analyses indicate that DNA methylation levels at CGIs increase with
disease severity from benign tissue to PCa onto CRPC. There was
also a less systematic and less pronounced average trend toward
DNA methylation increase with disease severity in non-CGI regions
(Figure 4A). Nevertheless, DNA methylation levels in CRPC were
highly variable among cases. To further investigate the global DNA
methylation increase, we focused on CGIs and performed gene ontology
analysis of the genes near CGIs that were differentially methylated
in PCa and CRPC using iPAGE [25] (LIMMA analysis, FDR = 5%;
Figure W3A). Interestingly, the genes associated with hypermethylated
CGIs had specific enrichments related to G-protein signaling, cAMP-
mediated signaling, and hormone activity. This suggests thatDNA
methylation increases during the transition between indolent PCa and
highly aggressive CRPC are at least partially functionally coherent.
Wealso found that EGR1 mRNA levels are further decreased in CRPC
compared to PCa, implicating the potential role of EGR1 down-
regulation in enabling CGI hypermethylation (Figure W3B).
We then sought to identify a subset of these CGIs whose methyla-
tion increases with disease severity. We determined CGIs whose meth-
ylation levels increased systematically between benign prostate tissues
and PCa (LIMMA analysis, FDR = 5%, n = 692). We also performed
the same analysis for CGIs whose methylation levels increased consis-
tently and reproducibly between PCa and CRPC (LIMMA analysis,
FDR = 5%, n = 1229). We found that the overlap between two groups
of hypermethylated CGIs was higher than expected (P < 1e−104,
hypergeometric P value; Figure 4B). This indicates that, to a large
extent, the same genomic regions gain methylation in the transition
from benign prostate tissue to PCa, and this trend continues onto
CRPC. There were 228 CGIs in this overlap and the DNA methyla-
tion heat map of the 228 CGIs provided a visual demonstration of the
positive association between PCa disease progression and increasing
DNA methylation levels (Figure W3C ). Cluster analysis based on
CGI methylation not only further confirmed the strong DNA methyl-
ation signature uncovered here but also showed that some PCa samples
clustered with CRPC samples, suggesting a propensity of these cases to
Figure 2. DNA methylation patterns in benign prostate tissues are associated with certain types of mutations in PCa. (A) Percentage
of DNA methylation in matched benign tissues for various breakpoints. The width of the violin plots correlates with the fraction of
mutations with corresponding methylation levels (Y axis). NS, not significant. (B) Percentage of DNA methylation of CpG sites in benign
prostate tissues, where C>T, C>A/G mutations occur.
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progress toward a more advanced disease (Figure W3D). As a control,
we performed the same analysis for hypomethylated CGIs; in that
analysis, hypomethylated CGIs between benign tissues and PCa and
between PCa and CRPC did not overlap more frequently than
expected by chance (Figure W3E). These results indicate that unlike
hypermethylation, hypomethylation may occur randomly during
progression to advanced PCa. Likewise, when we analyzed ASM in
CRPC, we found that ASM occurred at the same levels as benign pros-
tate tissues (Figure W3F).
We then sought to validate these observations on an independent
patient cohort. We integrated gene expression from the RNA-seq
data with the 228 CGIs and selected a panel of 13 CGIs for valida-
tion (Table W3). The 13 CGIs showed persistently increasing hyper-
methylation from benign prostate tissues to PCa, and from PCa to
CRPC, while genes associated with these CGIs also demonstrated dif-
ferential expression (LIMMA, FDR = 5%, fold change > 1.5). Among
the panel of 13 CGIs, three associated genes, general receptor for
phosphoinositides (GRASP), glutathione S-transferase π 1 (GSTP1), and
tropomyosin 4 (TPM4), have been reported as differentially methylated
in PCa versus normal tissues in Mahapatra et al. [8], thus providing
independent validation of our analysis. Tissues from FFPE blocks of
an independent cohort of 20 benign prostate tissues and 16 PCa and
8 CRPC samples were used to examine the panel of 13 CGIs. We used
MassARRAY EpiTYPER assay to directly interrogate methylation of
the 13 CGIs, thus seeking not only biologic validation in an indepen-
dent cohort but also technical validation of the methylation measure-
ments provided by ERRBS. As shown in Figure 4, C and D, we
observed the same increase inDNAmethylation correlating with disease
severity in FFPE samples using MassARRAY EpiTYPER assay as that
revealed by ERRBS on frozen tissues. We found that all 13 CGIs had
increased methylation levels between benign and primary PCa cases
(FDR= 5%); 8 of the 13CGIs had increasedmethylation levels between
primary cases and CRPC. Intriguingly, four advanced cases (FF18, 55,
57, and 59) that had no previous treatment showed high levels of DNA
Figure 3. Allele-specific DNA methylation is highly frequent in PCa. (A) Methylated and non-methylated CpGs correlate with the presence
or absence of a nearby SNP in the first pair of benign prostate tissue and PCa. (B) Fraction of CpGs associated with ASM in benign pros-
tate tissue and PCa. Only CpGs with a nearby SNP are considered in this analysis. (C) Fraction of CpGs with ASM in hypermethylated or
hypomethylated CGIs. (D) Fraction of regions containing at least one CpG with ASM in hypermethylated or hypomethylated DMRs.
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methylation at these selected CGIs. Using Random Forests [27], we
built two binary classification models to discriminate benign prostate
tissues from PCa, as well as PCa from CRPC, based on the methylation
levels of the 13CGIs. In 10-fold cross-validation, the AUC scores for the
predictive models were high, 0.9375 and 0.975, respectively
(Figure 4E), indicating a high sensitivity and specificity. Taken together,
our data suggest that both models provide excellent discriminatory
power and the panel may be useful in predicting disease aggressiveness
at diagnosis.
Discussion
In this study, we performed global DNA methylation profiling in
primary PCa samples, matched benign prostate tissues, and CRPC
and integrated DNA methylation patterns with whole-genome and
transcriptome sequencing data. We used ERRBS to profile genome-
wide DNA methylation status, thus interrogating >2.5 M single CpGs
in each sample. ERRBS has recently been developed to capture more
broadly genome-wide DNA methylation at single-base resolution,
including CGI shores [18]. ERRBS yields quantitative comparisons
Figure 4. DNA methylation increases with and may predict disease severity. (A) Percentage of DNA methylation in CGIs and non-CGIs of
benign prostate tissues (Ben), PCa, and CRPC. (B) Venn diagram displays the methylation overlap observed between two sections:
increased methylation from benign prostate tissues to PCa and increased methylation from PCa to CRPC; the inset number represents
the coverage in each section. Two hundred twenty-eight CGIs appear in both sections with P < 1e−104. (C) Left: Heat map of DNA
methylation levels of the panel of 13 CGIs in the three groups, 20 benign prostate tissues and 16 PCa and 8 CRPC samples (value range,
0 to 1). Right: Comparison between the three groups with adjusted log P values (Benjamini-Hochberg correction FDR controlled at 0.05).
(D) Boxplots of the average DNA methylation levels of the panel for individual samples. (E) Boxplots of the average DNA methylation
levels of the panel for the three groups. The AUC, sensitivity, and specificity for the comparison of benign and PCa are 0.9375, 100%,
and 75%, and those for the comparison of PCa and CRPC are 0.975, 95%, and 95%.
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of methylation levels and enhances methylation detection at various
genomic regions. By providing deep coverage of regulatory regions,
especially CGIs, and low coverage of repeat regions (e.g., LINE1 ele-
ments), ERRBS enables a range of new analyses, including ASM analyses.
The analyses described in this study led to a number of new find-
ings. First, by examining global methylation patterns in benign pros-
tate tissue versus PCa versus CRPC, we found increasing levels of DNA
methylation at CGIs correlated with increasing severity of the disease.
As most CRPCs still retain AR expression, the methylation patterns ob-
served in this study may not be representative of most CRPCs. Our
motif analysis indicates that EGR1 DNA motifs are overrepresented
at hypermethylated CGIs in PCa and CRPC. Previous studies using
genome-wide chromatin immunoprecipitation (ChIP) assays in other
cell types have indeed shown that EGR1 binds heavily to CGIs [33].
Our analyses also showed that EGR1 mRNA and protein levels de-
creased with disease severity. These data suggest that down-regulation
of EGR1 may enable DNA methylation to accumulate at CGIs, per-
haps through the recruitment of CGI-binding protein complexes that
include DNA methyltransferase; however, a broader evaluation of
EGR1 expression and a further investigation of the role of EGR1 in
PCa disease progression are warranted. Of the 228 CGIs that showed
increasing methylation during disease progression, we selected a panel
of 13 CGIs for further validation, as the expression of their associated
genes also exhibited significant changes and they may play important
roles in PCa progression, especially toward a late stage and lethal neuro-
endocrine phenotype. We propose examination of the methylation
status of this panel of 13 CGIs as putative diagnostic and prognostic
biomarkers, which may aid in directing treatment decisions.
According to RNA-seq data, the majority of genes on this panel were
downregulated (70%, 9 of the 13 CGIs). GSTP1, a well-known DNA
methylation biomarker for PCa, was among the associated genes
shown to have a continuous decline in gene expression during PCa
disease progression. Its silencing may render prostate cells more sen-
sitive to environmental insults and consequently more susceptible to
genomic damage [6]. Capping protein (actin filament), gelsolin-like
(CAPG ), a proposed tumor suppressor in certain cancers [34], has
been shown to modulate cancer cell invasion in breast and PCa cell
lines [35]. Retinoic acid receptor responder 2 (RARRES2), also known
as chemerin or tazarotene-induced gene 2, was found to attract den-
dritic cells and macrophages to the site of inflammation [36]. As such,
down-regulation of RARRES2 may affect the dynamics of the PCa
microenvironment. TPM4 has been connected to human cancer, even
though its role is less clear. Invasive squamous cervical cancer showed
lower expression of TPM4, while lymph node metastasis in breast
cancer has a significant association with TPM4 up-regulation [37,38].
Family with sequence similarity 107, member A (FAM107A), also known
as DRR1 or TU3A, was previously reported to be downregulated and
deleted in renal cell carcinoma, and the expression of FAM107A inhib-
ited cell growth [39]. Filamin A interacting protein 1–like (FILIP1L)
has also been shown downregulated in ovarian cancer, and its down-
regulation is inversely correlated with promoter methylation and
advanced phenotype [40].
Furthermore, the association of gene-body methylation with active
gene expression has been found in human cells and other organisms
[41,42]. Similarly, T-box containing transcription factor (TBX1) was
found to have a hypermethylated CGI around its second exon and
elevated gene expression in our cohort. A functional link has previ-
ously been established between TBX1 and retinoic acid (RA) signaling
where overexpressed TBX1 inhibits RA signaling, in part, due to down-
regulation of ALDH1a2 and PCNA [43,44]. As down-regulation of
ALDH1a2 was detected in human PCa and in the TRAMP mouse
model of PCa [45,46], this study suggests a regulation of ALDH1a2
and RA signaling through up-regulation of TBX1 by DNA methyla-
tion during PCa progression. Likewise, the CGI that overlapped with
the second exon of potassium voltage-gated channel subfamily C
(KCNC2 ) was also hypermethylated in PCa, with concurrent up-
regulation of the gene. KCNC2 encodes a membrane protein for voltage-
gated potassium channel. Its function in PCa is unclear and may be
related to the neuroendocrine phenotype of CRPC in this cohort.
Intriguingly, both RARRES2 and TBX1 were identified in the panel
and related to aberrant regulation of RA signaling during PCa pro-
gression. Even though we found that their hypermethylation resulted
in opposite directions of gene expression (i.e., down-regulation in
RARRES2 and up-regulation in TBX1), the overall outcomemay down-
regulate the RA signaling.
Another important finding in our study is that certain breakpoints,
like deletion, tandem duplications, or interchromosomal transloca-
tions, are associated with distinct DNA methylation patterns in pre-
malignant prostate tissue. We also found that highly methylated CpG
sites are likely more fragile and more frequently targeted for somatic
base mutations during PCa tumorigenesis compared to unmethylated
CpGs. However, given that the benign tissues are benign glands taken
from a cancer-free region of the matched PCa patient, we cannot rule
out that epigenomic changes may have arisen in these morphologically
normal tissues. Thus, the methylation patterns detected in benign tis-
sues and associated with PCa breakpoints may not be present in the
truly normal tissues (e.g., from autopsy) taken from other individuals.
Altogether, our study points to an important role of the epigenome in
mediating or facilitating a broad range of genomic alterations in PCa.
Whether this role is more central in PCa than in other malignancies
is currently unclear.
Our study revealed for the first time (to the best of our knowledge)
frequent ASM changes in PCa. It also showed that a vast fraction of
DNA methylation changes might occur on a single-allele basis. The
mechanisms behind these single-allele methylation changes are unclear
and may involve differential binding of transcription factors to each
allele due to the presence of SNPs or different nuclear localization pat-
terns. ASM was recently found at the H3K27me3-bound regions
in a study of bisulfite sequencing of chromatin-immunoprecipitated
DNA using PCa cell lines [30]. Thus, it is possible that a complex
interplay exists between DNA methylation and H3K27me3, and this
interplay precludes changes from occurring on certain alleles marked
with either epigenetic mark.
Recent large-scale genome-wide DNA methylation profiling studies
have discovered large numbers of DMRs. Our analysis on paired
samples further identified a consistent trend in many DMRs located
similarly across the entire genome, suggesting that DNA methylation
changes may follow certain genetic cues during PCa pathogenesis.
Moreover, we noted that within paired samples hypermethylation
was significantly correlated with down-regulation of gene expression,
while hypomethylation associates with up-regulation. Although this
concept is broadly used, recent genome-wide studies have observed
more complex regulations [18,42].
Both hypermethylation and hypomethylation take place in PCa
as well as other types of cancer. On the basis of the analysis of
5-methylcytosine content of genomic DNA, previous studies have
suggested that hypomethylation occurs later in course of metastatic
PCa [13,14]. In contrast, through the use of sequencing-based DNA
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methylation analysis, the results from this study and that of Kim et al.
did not find decreased CpG methylation levels of metastatic PCa [10].
However, our approach is biased toward regions of high guanine-
cytosine (GC) content, and LINE-1 and other repetitive regions shown
to be hypomethylated during PCa progression are underrepresented by
ERRBS; it stands to reason that a significant amount of hypomethyla-
tion may occur later at low or intermediate GC content regions, which
are not adequately represented by ERRBS or M-NGS.
Gene fusions between members of the ETS family and the androgen-
regulated TMPRSS2 are frequently detected in PCa [47]. Differences
in global methylation patterns or LINE-1 methylation were reported
when categorizing PCa according to ETS gene fusion status [10,11].
Consistent with the study of Kim et al., we observed lower global
methylation in TMPRSS2:ERG fusion-negative PCa (Figure W4), in
contrast to the study of Borno et al., which showed increased levels of
global methylation in the fusion-negative PCa. This discrepancy may
be explained by the different approaches that were employed in these
studies, as the levels of GC content coverage varied considerably: both
ERRBS andM-NGS focus on regions of highGC content withminimal
coverage of repeat elements, while MeDIP-seq has a broader coverage
over CpGs in repetitive elements [48].
From a clinical point of view, the robust observation that DNA
methylation increases with disease severity, especially at CGIs, provides
new opportunities for detecting and diagnosing advanced PCa earlier
than currently possible and for assisting treatment decisions. As a first
step toward this goal, we provide a panel of 13 CGIs whose methyla-
tion reliably and reproducibly increases with disease severity, including
association with a late stage and lethal neuroendocrine phenotype.
Classification models based on the DNA methylation levels of these
13 CGIs and using Random Forest analysis deliver great discriminatory
power, pointing toward a potential clinical use of the panel.
Larger studies with long-term follow-up, and inclusion of various
stages of disease progression including CRPCs with retained AR expres-
sion, will be required to assess the true clinical value of these 13 CGIs
and of other epigenetic alterations in the diagnosis, prognosis, and
treatment of PCa.
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Table W1. Clinical Parameters of Samples Used in ERRBS.
PCa STID No. Serum PSA (ng/ml) Age at Diagnosis Gleason Score (H&E) Pathological Stage EST-Fusion Status Year of Radical Prostatectomy
1 508 7.8 57 3 + 4 = 7 T2c NEG 2007
2 581 9.2 69 4 + 5 = 9 T3b POS 2007
3 1701 2.1 62 3 + 4 = 7 T3a POS 2007
4 1783 9.8 66 4 + 4 = 8 T2c NEG 2008
5 2832 6.6 66 3 + 4 = 7 T2c POS 2007
6 3027 10.2 66 4 + 4 = 8 T3b NEG 2008
7 3043 7.2 69 3 + 4 = 7 T2c NEG 2008
CRPC STID No. Serum PSA (ng/ml) Age at Diagnosis Metastatic AR Status Overall Survival EST-Fusion Status Tissue Type
1 4240 1.93 74 – (−) 13 months NEG NEPC
2 7520 0.06 56 Yes (−) Alive POS NEPC
3 7820 – – – (−) 9 months NEG NEPC
4 7821 – – – (−) 9 months NEG NEPC
5 8220 – – – (−) – NEG NEPC
6 8740 48.5 59 Yes (−) 3 months NEG NEPC
Table W2. Clinical Parameters of FFPE Samples of PCa and CRPC Used in the Validation Cohort.
PCa STID No. Serum PSA (ng/ml) Age at Diagnosis Gleason Score (H&E) Pathological Stage Benign in the Cohort Year of Radical Prostatectomy
FF23 S10-25464 15 74 4 + 3 = 7 T2c FF22 2010
FF25 S10-17814 5.94 70 3 + 4 = 7 T2a FF24 2010
FF29 S10-29475 7.4 69 4 + 5 = 9 T3a FF28 2010
FF31 S09-21599 5.6 62 3 + 4 = 7 T2c FF30 2009
FF33 S08-6573 – 65 3 + 4 = 7 T2c FF32 2008
FF35 S08-25678 4.98 68 4 + 3 = 7 T2c FF34 2008
FF37 S08-15334 – 58 4 + 3 = 7 T3a FF36 2008
FF39 S07-30717 8.8 63 3 + 4 = 7 T3b FF38 2007
FF41 S07-29284 5.4 61 3 + 4 = 7 T2c n/a 2007
FF43 S07-30675 – 50 3 + 4 = 7 T2c FF42 2007
FF45 S07-28150 – 58 3 + 4 = 7 T2c FF44 2007
FF47 S07-28191 – 57 3 + 4 = 7 T2c FF46 2007
FF49 S07-30522 – 63 3 + 4 = 7 T2c FF48 2007
FF51 S07-31303 – 60 3 + 4 = 7 T2c FF50 2007
FF53 S07-29250 – 55 3 + 3 = 6 T2a FF52 2007
FF63 S06-1447 3.15 55 5 + 4 = 9 T4 n/a 2006
CRPC STID No. Tissue Type Serum PSA (ng/ml) Age at Diagnosis Metastatic Prior Chemotherapy AR Status Benign in the Cohort
FF12 1633/04 NEPC – – – – (+) n/a
FF14 10586 NEPC – – – – (−) FF13
FF16 21771/07 NEPC – – – – (+) FF15
FF18 S05-31294 NEPC 5.9 63 – No (+) FF17
FF20 S10-5780 NEPC – 69 yes Yes (−) FF19
FF55 S97-1161 NEPC – 78 – No (+) n/a
FF57 S02-1928 NEPC – 79 yes No (+) n/a
FF59 S12-2609 NEPC 0.7 65 yes No (−) FF58
Figure W1. Possible involvement of EGR1 in DNA hypermethylation. (A) Motif analysis of hypermethylated and hypomethylated CGIs.
(B) EGR1 mRNA expression between benign prostate tissues and PCa. (C) Immunohistochemistry staining of EGR1 in patient 4 is shown
here. Left: ×20; scale bar, 100 μm; right: ×40.
Figure W2. PCR duplicates and clonal reads do not explain differ-
ences in ASM. Clonality rate for 10 million reads in benign prostate
tissue and PCa.
Figure W3. Pathway analysis and comparison between PCa and CRPC. (A) The enriched pathways associated with DNA methylation
status in CRPC; red, enrichment; blue, depletion. (B) EGR1 mRNA expression between PCa and CRPC. (C) Heat map of the 228 CGIs.
(D) Cluster dendrogram of PCa and CRPC using the 228 CGIs. (E) Venn diagram displays the methylation overlap observed between two
sections: decreased methylation from benign prostate tissues to PCa and decreased methylation from PCa to CRPC; the inset number
represents the coverage in each section. Five CGIs appear in both sections with P = .01. (F) Percentage of CpG with ASM in PCa and
CRPC. Only CpG with nearby SNPs are used for this analysis.
Table W3. The Panel of the 13 CGIs and the Associated Genes.
No. Chr Start End Gene Description DIST EXP Benign PCa CRPC
1 chr12 75601081 75601752 KCNC2 Potassium voltage-gated channel subfamily C 2095 Up 4.644 6.035 11.677
2 chr16 67427284 67428950 ZDHHC1 Probable palmitoyltransferase ZDHHC1 204 Down 8.21 7.266 5.733
3 chr22 19746924 19747141 TBX1 T-box transcription factor TBX1 isoform C 2808 Up 2.078 3.865 9.733
4 chr2 85640969 85641259 CAPG Macrophage-capping protein 83 Down 22.958 11.654 8.677
5 chr7 150037459 150039031 RARRES2 Retinoic acid receptor responder protein 2 518 Down 77.08 48.548 15.319
6 chr12 52400467 52401696 GRASP General receptor for phosphoinositides 335 Down 9.953 4.452 2.018
7 chr11 64815040 64815722 SAC3D1 SAC3 domain-containing protein 1 3081 Up 4.907 6.564 19.878
8 chr19 16186789 16188275 TPM4 Tropomyosin α-4 chain isoform 2 398 Down 42.185 23.212 14.138
9 chr11 67350928 67351953 GSTP1 Glutathione S -transferase P 376 Down 168.097 62.937 42.57
10 chr14 36991594 36992488 NKX2-1 Homeobox protein Nkx-2.1 isoform 2 2611 Up 0.014 1.817 66.708
11 chr3 58572478 58572903 FAM107A Downregulated in renal cell carcinoma 9200 Down 18.921 3.797 1.016
12 chr20 45279781 45280169 SLC13A3 Solute carrier family 13 member 3 isoform a 125 Down 6.766 6.334 3.648
13 chr3 99594969 99595215 FILIP1L Filamin A interacting protein 1–like isoform 1 46 Down 22.005 5.101 1.525
Figure W4. DNAmethylation levels in TMPRSS2:ERG fusion-positive
and fusion-negative samples.
Table W4. MassARRAY EpiTYPER Primers of the 13 CGIs.
No. Chr Start End Gene DIST Forward Reverse
Epi1 chr12 75601081 75601752 KCNC2 2095 aggaagagagGTAGTATTTTTAAGATTTTGTTTGGAAT cagtaatacgactcactatagggagaaggctATACCCCAAAAAACCAACTCCT
Epi2 chr16 67427284 67428950 ZDHHC1 204 aggaagagagGGTTTTTTGAGGAAATAGTTTTTTA cagtaatacgactcactatagggagaaggctTACTCCAAACTCTAAATCCTACCCA
Epi3 chr22 19746924 19747141 TBX1 2808 aggaagagagAAGAGGGTTTTGTATTTTTAGGGTG cagtaatacgactcactatagggagaaggctCTAAAAACTCACCTTCCATATCCCT
Epi4 chr2 85640969 85641259 CAPG 83 aggaagagagGGTTGTTATTAGTTTTAAGTGGGGG cagtaatacgactcactatagggagaaggctACCTAAAAACTCACCTTCCATATCC
Epi5 chr7 150037459 150039031 RARRES2 518 aggaagagagGGAGATTTAGGGAGAGATATAATGGG cagtaatacgactcactatagggagaaggctATAAAATTCCTCCAAAACCACCTAC
Epi6 chr12 52400467 52401696 GRASP 335 aggaagagagAGGGATAGAGATAGTTTTAGGTAAGTTGA cagtaatacgactcactatagggagaaggctAAAAATCCAAAAAACAATAACCCTC
Epi7 chr11 64815040 64815722 SAC3D1 3081 aggaagagagTTTTTTTATTTTTTTGGTTGTAGAGAAG cagtaatacgactcactatagggagaaggctAAAACCCAAATAATCTTTCTCCCCT
Epi8 chr19 16186789 16188275 TPM4 398 aggaagagagGAGGGAAAGATGTGAAAATTTTATT cagtaatacgactcactatagggagaaggctCCACAACTACTAAAAAATACCCCTT
Epi9 chr11 67350928 67351953 GSTP1 376 aggaagagagTTTTGTTGTTTGTTTATTTTTTAGG cagtaatacgactcactatagggagaaggctTACTAAAAACTCTAAACCCCATCCC
Epi10 chr14 36991594 36992488 NKX2-1 2611 aggaagagagGGGAAGAGAAGGATATTTGTATTTTT cagtaatacgactcactatagggagaaggctTTAAACCCTACCCTACCCTAACC
Epi11 chr3 58572478 58572903 FAM107A 9200 aggaagagagGTTTTTTATTGTAGAGTTAGTATTGTTGG cagtaatacgactcactatagggagaaggctACACCTACCCTAACCCCTACCC
Epi12 chr20 45279781 45280169 SLC13A3 125 aggaagagagGATTTAGAAGGTAGGGTGGGATTTA cagtaatacgactcactatagggagaaggctCTTTTCCTCCAAAAAAAACAAAAAA
Epi13 chr3 99594969 99595215 FILIP1L 46 aggaagagagGATTTGTTATTTGGTTGTTTGATAG cagtaatacgactcactatagggagaaggctTACCTCCCAATAACTTTATTAACCC
